ERBB2 and breast carcinoma: Lastly, miR-29b is elevated in the ER+ (luminal molecular subtypes) compared with TNBC (basal-like) and HER2-enriched breast tumors [30], indicating that different mechanisms must be activated in breast cancer cells with different phenotypes.